Global Next Generation Gynecological Cancer Diagnostic Market Overview

The Global Next Generation Gynecological Cancer Diagnostic Market size is expected to grow from USD 2.41 billion in 2022 to USD 5.43 billion by 2030, at a CAGR of 10.70% during the forecast period (2023-2030).

Cancer that originates in a woman's reproductive organs is referred to as gynecologic cancer. Cancer is always named after the body part where it first appears. Gynecologic cancers can start anywhere in a woman's pelvis, which is the area beneath the stomach and between hip bones. Cervical, ovarian, uterine, vaginal, and vulvar cancers are several types of gynecologic cancer. Ovarian cancer is the most common gynecologic cancer.

Advancement in technology has resulted in the development of innovative techniques for the diagnosis of gynecologic cancer such as quantitative polymerase chain reaction (qPCR) & multiplexing, next-generation sequencing, and lab-on-a-chip (LOAC) & reverse transcription-polymerase chain reaction (RT-PCR), and microarray. Advancements in the technologies of sequencing have supported researchers, and clinics to get knowledge which further helped to discover biomarkers for guidance. According to WHO, cancer is the leading cause of death across the globe, with approximately 10 million deaths in 2020. In the same year, about 342,000 women died due to cervical cancer. The growing prevalence of cervical cancer and the supportive government initiatives to prevent fatalities is expected to support the development of the next generation of gynecological cancer diagnostic over the forecasted timeframe.

Market Dynamics And Factors Next Generation Gynecological Cancer Diagnostic Market

Drivers:

Growing Prevalence of Cervical & Ovarian Cancer

The increase in the number of gynecological cancer cases is the main factor stimulating the development of next-generation gynecological cancer diagnoses during the analysis period. Breast cancer is the most common cancer diagnosed in women worldwide, whereas, with an estimated 604,000 new cases in 2020, cervical cancer is the fourth most common cancer in women. Around 90% of the estimated 342,000 cervical cancer deaths in 2020 will occur in low- and middle-income countries. HIV-positive women are six times more likely than HIV-negative women to acquire cervical cancer, with HIV accounting for about 5% of all cervical cancer cases. Furthermore, HIV contributes disproportionately to cervical cancer in younger women in all world regions.

Ovaries are a part of the female reproductive system, and ovarian cancer occurs when abnormal cells in the ovary begin to proliferate and divide uncontrollably. The most frequent kind of ovarian cancer is epithelial ovarian cancer. Primary peritoneal cancer and fallopian tube cancer are both treated the same way as epithelial ovarian cancer. Germ cell tumors (teratomas and dysgerminomas), stromal tumors (granulosa tumors), and sarcomas are all rare kinds of ovarian cancer. According to a WHO report, 314,000 females were diagnosed with ovarian cancer in 2020, and this number is expected to reach 429,000 by 2040. The fatalities were 207,000 in 2020 which is anticipated to reach 306,000 by 2040. Thus, the growing cases of ovarian and cervical cancer are expected to boost the expansion of the next-generation gynecological cancer diagnostic market over the analysis period.

Restraints: 

Low Funding and Restricted Usage of Innovative Diagnostics Techniques

Techniques involved in next-generation cancer diagnostics are new to the world, and there is a need for more research to validate their effectiveness in diagnostic procedures. Next-Generation Sequencing techniques are Laboratory Developed Tests (LDTs). There are very few laboratories that offer NGS for diagnostics as a skilled labor force is required. Regulatory policies regarding the development and usage of NGS are very strict. In order to get an FDA approval for NGS based in vitro diagnostics technique, the expenditure can cost between USD 20 to 30 million thus, the high developmental cost has restricted the commercialization of NGS diagnostic tests. Furthermore, in developing regions individuals are unaware of the advantages of next-generation diagnostics. In addition, developing regions lack the required funds for the procurement of hardware required for the setup of laboratories thus, hampering the development of the market.

Opportunities:

Government Initiatives to Reduce the Cancer Burden

By avoiding risk factors and adapting evidence-based prevention strategies, 30 to 50 % of cancers can be avoided. Early detection, as well as adequate treatment and care for cancer patients, can help in decreasing the cancer burden. Many cancers have a good possibility of being cured if detected early and treated appropriately. Several governments have taken steps to combat the spread of noncommunicable diseases. Noncommunicable diseases, such as cardiovascular disease, cancer, chronic respiratory disease, diabetes, and others, are thought to account for over 60% of all deaths in India.

The National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) was started in 2010 with an emphasis on infrastructure, human resource development, health promotion, early diagnosis, management, and referral to prevent and control major NCDs. The Government of India has launched the Tertiary Care Cancer Centers (TCCC) initiative, which aims to establish/strengthen 20 State Cancer Institutes (SCI) and 50 TCCCs across the country to provide comprehensive cancer care. A 'one-time grant' of USD 15 million for each SCI and USD 6 million per TCCC is provided under the scheme, to be used for building construction and equipment procurement. Similar initiatives by other governments are expected to create opportunities for market players.

Segmentation Analysis Of Next Generation Gynecological Cancer Diagnostic Market

By technology, the Next Generation Sequencing segment is anticipated to develop at the highest CAGR over the forecasted timeframe. Next-Generation Sequencing has proven to be a valuable tool for obtaining a deeper and more precise look into the molecular underpinnings of individual tumors. When compared to traditional approaches, NGS has the potential to have a significant impact on the field of oncology due to its accuracy, sensitivity, and speed. Since NGS can test numerous genes in a single assay, it eliminates the need for multiple tests to find the causative mutation thus, supporting the development of the segment.

By function, the companion diagnostics segment is anticipated to dominate the next-generation gynecological cancer diagnostic market over the forecasted timeframe. Companion diagnostics assist healthcare professionals in determining a patient's response to a specific agent to improve cancer patient outcomes and improve personalized medicine. This also aids in the reduction of rising healthcare expenses by limiting drug use to only those who will significantly benefit from it thus, strengthening the expansion of the segment in the projected period.  

By application, the biomarker development segment is expected to lead the development of the next-generation gynecological cancer diagnostic market. Patients with the same cancer type used to get the same treatment, but research has shown that tumors, even within the same cancer type, have distinct characteristics. Physicians are increasingly relying on cancer biomarkers to learn more about a patient's tumor and predict which treatment will be most effective against their specific cancer. Biomarkers can be utilized to personalize therapy for individual patients, reducing treatment costs.

Regional Analysis Of Next Generation Gynecological Cancer Diagnostic Market

The North American region is anticipated to dominate the next-generation cancer diagnostics market over the forecasted period attributed to the growing prevalence of ovarian cancer. According to the American Cancer Society, about 19,880 women in the United States will receive a new diagnosis of ovarian cancer in 2022. The Society also estimated that 12,810 women will die from ovarian cancer. Ovarian cancer is the sixth leading cause of cancer death in women, accounting for more fatalities than any other cancer of the female reproductive system. A woman's lifetime risk of developing ovarian cancer is roughly 1 in 78. Her lifetime chance of dying from ovarian cancer is approximately 1 in 108. This cancer primarily affects older women. About half of the women diagnosed with ovarian cancer are 63 or older. The increasing geriatric population coupled with the rise in the number of gynecologic cancer cases are the main factors supporting the development of the market in this region.

The European region is expected to have the second-highest share of the next-generation cancer diagnostics market in the analysis period. Cervical cancer is predicted to account for 2.5 % of cancer cases (excluding non-melanoma skin cancers) identified in women in 2020, and 2.4 % of all cancer deaths in women. Cervical cancer is the 11^th most common cancer in women and the 12^th most common cause of cancer death in them. In 2020, estimated cervical cancer incidence rates differed fivefold and fatality rates eightfold throughout the EU-27. This wide range can be attributed to differences in HPV prevalence, vaccination, and cervical cancer screening strategies between EU countries. The presence of prominent key players and rise in the R&D activities to develop innovative gynecological cancer diagnostic procedures are expected to support the growth of the market in this region.

The next-generation cancer diagnostics market in the Asia-Pacific region is anticipated to develop at the highest CAGR over the analysis period. According to ICO/IARC Information Centre on HPV and Cancer, every year 123,907 women in India are diagnosed with cervical cancer, and 77,348 die from the disease. Cervical cancer is the second most common disease among women in India, and the second most common cancer among women aged 15 to 44. Moreover, the growing prevalence of ovarian, uterine, vaginal, and vulvar cancer cases in Japan, China, Indonesia, Singapore, and South Korea is expected to propel the growth of the next-generation cancer diagnostics market in this region.

COVID 19 Impacts On Next Generation Gynecological Cancer Diagnostic Market

The COVID-19 pandemic significantly affected cancer diagnostics procedures. Innovative diagnostics procedures that were under trial were halted to curb the spread of the novel coronavirus. According to a Lancet study, cancer services in India, such as new patient registrations, outpatient treatments, hospital admissions, and major surgeries, decreased between March and May 2020, compared to the same period in 2019. It was discovered that these interruptions might result in 83,600-111,500 people seeking cancer care for more advanced conditions during the next two years. Excess cancer-related fatalities in the following five years might range from 98,650 to 131,500, according to the report. To summarize, the R&D activities are expected to increase as the COVID cases decrease attributed to the growing vaccination rate. Market players are expected to launch advanced diagnostics techniques to recuperate from the COVID-19 pandemic.

Top Key Players Covered In Next Generation Gynecological Cancer Diagnostic Market

• Agilent Technologies (California, United States)
• ARUP Laboratories (California, United States)
• BGI Genomics (Shenzhen, China)
• CENTOGENE N.V. (Rostock, Germany)
• F. Hoffmann-La Roche Ltd (Basel, Switzerland)
• Fulgent Genetics (California, United States)
• Illumina Inc. (California, United States)
• Invitae Corporation (California, United States)
• Konica Minolta Inc. (Tokyo, Japan)
• Laboratory Corporation of America Holdings (California, United States)
• Myriad Genetics (Utah, United States)
• OPKO Health Inc. (Florida, United States)
• QIAGEN N.V. (Germany)
• Quest Diagnostics Incorporated (US)
• Thermo Fisher Scientific Inc. (US) and Other Major Players.

Key Industry Developments In The Next Generation Gynecological Cancer Diagnostic Market

In May 2022, Agilent Technologies Inc. announced that their PD-L1 IHC 22C3 pharmDx, Code SK006, has received EU CE-IVD approval for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can help identify cervical cancer patients who may benefit from treatment with KEYTRUDA® (pembrolizumab).

In February 2021, QIAGEN and INOVIO Pharmaceuticals have announced a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic solutions based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.

In July 2020, Thermo Fisher Scientific signed a CDx agreement with Chugai Pharmaceutical and has applied to the Ministry of Health, Labor, and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Technology
 3.2 By Function
 3.3 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Next Generation Gynecological Cancer Diagnostic Market by Technology
 5.1 Next Generation Gynecological Cancer Diagnostic Market Overview Snapshot and Growth Engine
 5.2 Next Generation Gynecological Cancer Diagnostic Market Overview
 5.3 qPCR & Multiplexing
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 qPCR & Multiplexing: Grographic Segmentation
 5.4 Next-Generation Sequencing
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Next-Generation Sequencing: Grographic Segmentation
 5.5 LOAC & RT-PCR
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 LOAC & RT-PCR: Grographic Segmentation
 5.6 Other
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Other: Grographic Segmentation

Chapter 6: Next Generation Gynecological Cancer Diagnostic Market by Function
 6.1 Next Generation Gynecological Cancer Diagnostic Market Overview Snapshot and Growth Engine
 6.2 Next Generation Gynecological Cancer Diagnostic Market Overview
 6.3 Companion Diagnostics
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Companion Diagnostics: Grographic Segmentation
 6.4 Therapeutic & Monitoring
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Therapeutic & Monitoring: Grographic Segmentation
 6.5 Prognostic
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Prognostic: Grographic Segmentation
 6.6 Cancer
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Cancer: Grographic Segmentation
 6.7 Screening
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Screening: Grographic Segmentation
 6.8 Risk Analysis
  6.8.1 Introduction and Market Overview
  6.8.2 Historic and Forecasted Market Size (2016-2028F)
  6.8.3 Key Market Trends, Growth Factors and Opportunities
  6.8.4 Risk Analysis: Grographic Segmentation

Chapter 7: Next Generation Gynecological Cancer Diagnostic Market by Application
 7.1 Next Generation Gynecological Cancer Diagnostic Market Overview Snapshot and Growth Engine
 7.2 Next Generation Gynecological Cancer Diagnostic Market Overview
 7.3 Biomarker Development
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Biomarker Development: Grographic Segmentation
 7.4 CTC Analysis
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 CTC Analysis: Grographic Segmentation
 7.5 Proteomic Analysis
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Proteomic Analysis: Grographic Segmentation
 7.6 Epigenetic Analysis
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size (2016-2028F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Epigenetic Analysis: Grographic Segmentation
 7.7 Others
  7.7.1 Introduction and Market Overview
  7.7.2 Historic and Forecasted Market Size (2016-2028F)
  7.7.3 Key Market Trends, Growth Factors and Opportunities
  7.7.4 Others: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Next Generation Gynecological Cancer Diagnostic Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Next Generation Gynecological Cancer Diagnostic Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Next Generation Gynecological Cancer Diagnostic Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 AGILENT TECHNOLOGIES
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 ARUP LABORATORIES
 8.4 BGI GENOMICS
 8.5 CENTOGENE N.V.
 8.6 F. HOFFMANN-LA ROCHE LTD
 8.7 FULGENT GENETICS
 8.8 ILLUMINA INC
 8.9 INVITAE CORPORATION
 8.10 KONICA MINOLTA INC.
 8.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
 8.12 MYRIAD GENETICS
 8.13 OPKO HEALTH INC.
 8.14 QIAGEN N.V.
 8.15 QUEST DIAGNOSTICS INCORPORATED
 8.16 THERMO FISHER SCIENTIFIC INC
 8.17 OTHER MAJOR PLAYERS

Chapter 9: Global Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Technology
  9.2.1 qPCR & Multiplexing
  9.2.2 Next-Generation Sequencing
  9.2.3 LOAC & RT-PCR
  9.2.4 Other
 9.3 Historic and Forecasted Market Size By Function
  9.3.1 Companion Diagnostics
  9.3.2 Therapeutic & Monitoring
  9.3.3 Prognostic
  9.3.4 Cancer
  9.3.5 Screening
  9.3.6 Risk Analysis
 9.4 Historic and Forecasted Market Size By Application
  9.4.1 Biomarker Development
  9.4.2 CTC Analysis
  9.4.3 Proteomic Analysis
  9.4.4 Epigenetic Analysis
  9.4.5 Others

Chapter 10: North America Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Technology
  10.4.1 qPCR & Multiplexing
  10.4.2 Next-Generation Sequencing
  10.4.3 LOAC & RT-PCR
  10.4.4 Other
 10.5 Historic and Forecasted Market Size By Function
  10.5.1 Companion Diagnostics
  10.5.2 Therapeutic & Monitoring
  10.5.3 Prognostic
  10.5.4 Cancer
  10.5.5 Screening
  10.5.6 Risk Analysis
 10.6 Historic and Forecasted Market Size By Application
  10.6.1 Biomarker Development
  10.6.2 CTC Analysis
  10.6.3 Proteomic Analysis
  10.6.4 Epigenetic Analysis
  10.6.5 Others
 10.7 Historic and Forecast Market Size by Country
  10.7.1 U.S.
  10.7.2 Canada
  10.7.3 Mexico

Chapter 11: Europe Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Technology
  11.4.1 qPCR & Multiplexing
  11.4.2 Next-Generation Sequencing
  11.4.3 LOAC & RT-PCR
  11.4.4 Other
 11.5 Historic and Forecasted Market Size By Function
  11.5.1 Companion Diagnostics
  11.5.2 Therapeutic & Monitoring
  11.5.3 Prognostic
  11.5.4 Cancer
  11.5.5 Screening
  11.5.6 Risk Analysis
 11.6 Historic and Forecasted Market Size By Application
  11.6.1 Biomarker Development
  11.6.2 CTC Analysis
  11.6.3 Proteomic Analysis
  11.6.4 Epigenetic Analysis
  11.6.5 Others
 11.7 Historic and Forecast Market Size by Country
  11.7.1 Germany
  11.7.2 U.K.
  11.7.3 France
  11.7.4 Italy
  11.7.5 Russia
  11.7.6 Spain
  11.7.7 Rest of Europe

Chapter 12: Asia-Pacific Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Technology
  12.4.1 qPCR & Multiplexing
  12.4.2 Next-Generation Sequencing
  12.4.3 LOAC & RT-PCR
  12.4.4 Other
 12.5 Historic and Forecasted Market Size By Function
  12.5.1 Companion Diagnostics
  12.5.2 Therapeutic & Monitoring
  12.5.3 Prognostic
  12.5.4 Cancer
  12.5.5 Screening
  12.5.6 Risk Analysis
 12.6 Historic and Forecasted Market Size By Application
  12.6.1 Biomarker Development
  12.6.2 CTC Analysis
  12.6.3 Proteomic Analysis
  12.6.4 Epigenetic Analysis
  12.6.5 Others
 12.7 Historic and Forecast Market Size by Country
  12.7.1 China
  12.7.2 India
  12.7.3 Japan
  12.7.4 Singapore
  12.7.5 Australia
  12.7.6 New Zealand
  12.7.7 Rest of APAC

Chapter 13: Middle East & Africa Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Technology
  13.4.1 qPCR & Multiplexing
  13.4.2 Next-Generation Sequencing
  13.4.3 LOAC & RT-PCR
  13.4.4 Other
 13.5 Historic and Forecasted Market Size By Function
  13.5.1 Companion Diagnostics
  13.5.2 Therapeutic & Monitoring
  13.5.3 Prognostic
  13.5.4 Cancer
  13.5.5 Screening
  13.5.6 Risk Analysis
 13.6 Historic and Forecasted Market Size By Application
  13.6.1 Biomarker Development
  13.6.2 CTC Analysis
  13.6.3 Proteomic Analysis
  13.6.4 Epigenetic Analysis
  13.6.5 Others
 13.7 Historic and Forecast Market Size by Country
  13.7.1 Turkey
  13.7.2 Saudi Arabia
  13.7.3 Iran
  13.7.4 UAE
  13.7.5 Africa
  13.7.6 Rest of MEA

Chapter 14: South America Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Technology
  14.4.1 qPCR & Multiplexing
  14.4.2 Next-Generation Sequencing
  14.4.3 LOAC & RT-PCR
  14.4.4 Other
 14.5 Historic and Forecasted Market Size By Function
  14.5.1 Companion Diagnostics
  14.5.2 Therapeutic & Monitoring
  14.5.3 Prognostic
  14.5.4 Cancer
  14.5.5 Screening
  14.5.6 Risk Analysis
 14.6 Historic and Forecasted Market Size By Application
  14.6.1 Biomarker Development
  14.6.2 CTC Analysis
  14.6.3 Proteomic Analysis
  14.6.4 Epigenetic Analysis
  14.6.5 Others
 14.7 Historic and Forecast Market Size by Country
  14.7.1 Brazil
  14.7.2 Argentina
  14.7.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET COMPETITIVE RIVALRY
TABLE 005. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET THREAT OF NEW ENTRANTS
TABLE 006. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET THREAT OF SUBSTITUTES
TABLE 007. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET BY TECHNOLOGY
TABLE 008. QPCR & MULTIPLEXING MARKET OVERVIEW (2016-2028)
TABLE 009. NEXT-GENERATION SEQUENCING MARKET OVERVIEW (2016-2028)
TABLE 010. LOAC & RT-PCR MARKET OVERVIEW (2016-2028)
TABLE 011. OTHER MARKET OVERVIEW (2016-2028)
TABLE 012. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET BY FUNCTION
TABLE 013. COMPANION DIAGNOSTICS MARKET OVERVIEW (2016-2028)
TABLE 014. THERAPEUTIC & MONITORING MARKET OVERVIEW (2016-2028)
TABLE 015. PROGNOSTIC MARKET OVERVIEW (2016-2028)
TABLE 016. CANCER MARKET OVERVIEW (2016-2028)
TABLE 017. SCREENING MARKET OVERVIEW (2016-2028)
TABLE 018. RISK ANALYSIS MARKET OVERVIEW (2016-2028)
TABLE 019. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET BY APPLICATION
TABLE 020. BIOMARKER DEVELOPMENT MARKET OVERVIEW (2016-2028)
TABLE 021. CTC ANALYSIS MARKET OVERVIEW (2016-2028)
TABLE 022. PROTEOMIC ANALYSIS MARKET OVERVIEW (2016-2028)
TABLE 023. EPIGENETIC ANALYSIS MARKET OVERVIEW (2016-2028)
TABLE 024. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY TECHNOLOGY (2016-2028)
TABLE 026. NORTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY FUNCTION (2016-2028)
TABLE 027. NORTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY APPLICATION (2016-2028)
TABLE 028. N NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY (2016-2028)
TABLE 029. EUROPE NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY TECHNOLOGY (2016-2028)
TABLE 030. EUROPE NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY FUNCTION (2016-2028)
TABLE 031. EUROPE NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY APPLICATION (2016-2028)
TABLE 032. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY (2016-2028)
TABLE 033. ASIA PACIFIC NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY TECHNOLOGY (2016-2028)
TABLE 034. ASIA PACIFIC NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY FUNCTION (2016-2028)
TABLE 035. ASIA PACIFIC NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY APPLICATION (2016-2028)
TABLE 036. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY TECHNOLOGY (2016-2028)
TABLE 038. MIDDLE EAST & AFRICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY FUNCTION (2016-2028)
TABLE 039. MIDDLE EAST & AFRICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY APPLICATION (2016-2028)
TABLE 040. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY (2016-2028)
TABLE 041. SOUTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY TECHNOLOGY (2016-2028)
TABLE 042. SOUTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY FUNCTION (2016-2028)
TABLE 043. SOUTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY APPLICATION (2016-2028)
TABLE 044. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET, BY COUNTRY (2016-2028)
TABLE 045. AGILENT TECHNOLOGIES: SNAPSHOT
TABLE 046. AGILENT TECHNOLOGIES: BUSINESS PERFORMANCE
TABLE 047. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 048. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. ARUP LABORATORIES: SNAPSHOT
TABLE 049. ARUP LABORATORIES: BUSINESS PERFORMANCE
TABLE 050. ARUP LABORATORIES: PRODUCT PORTFOLIO
TABLE 051. ARUP LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. BGI GENOMICS: SNAPSHOT
TABLE 052. BGI GENOMICS: BUSINESS PERFORMANCE
TABLE 053. BGI GENOMICS: PRODUCT PORTFOLIO
TABLE 054. BGI GENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. CENTOGENE N.V.: SNAPSHOT
TABLE 055. CENTOGENE N.V.: BUSINESS PERFORMANCE
TABLE 056. CENTOGENE N.V.: PRODUCT PORTFOLIO
TABLE 057. CENTOGENE N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. F. HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 058. F. HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 059. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 060. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. FULGENT GENETICS: SNAPSHOT
TABLE 061. FULGENT GENETICS: BUSINESS PERFORMANCE
TABLE 062. FULGENT GENETICS: PRODUCT PORTFOLIO
TABLE 063. FULGENT GENETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. ILLUMINA INC: SNAPSHOT
TABLE 064. ILLUMINA INC: BUSINESS PERFORMANCE
TABLE 065. ILLUMINA INC: PRODUCT PORTFOLIO
TABLE 066. ILLUMINA INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. INVITAE CORPORATION: SNAPSHOT
TABLE 067. INVITAE CORPORATION: BUSINESS PERFORMANCE
TABLE 068. INVITAE CORPORATION: PRODUCT PORTFOLIO
TABLE 069. INVITAE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. KONICA MINOLTA INC.: SNAPSHOT
TABLE 070. KONICA MINOLTA INC.: BUSINESS PERFORMANCE
TABLE 071. KONICA MINOLTA INC.: PRODUCT PORTFOLIO
TABLE 072. KONICA MINOLTA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. LABORATORY CORPORATION OF AMERICA HOLDINGS: SNAPSHOT
TABLE 073. LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS PERFORMANCE
TABLE 074. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 075. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. MYRIAD GENETICS: SNAPSHOT
TABLE 076. MYRIAD GENETICS: BUSINESS PERFORMANCE
TABLE 077. MYRIAD GENETICS: PRODUCT PORTFOLIO
TABLE 078. MYRIAD GENETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 078. OPKO HEALTH INC.: SNAPSHOT
TABLE 079. OPKO HEALTH INC.: BUSINESS PERFORMANCE
TABLE 080. OPKO HEALTH INC.: PRODUCT PORTFOLIO
TABLE 081. OPKO HEALTH INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 081. QIAGEN N.V.: SNAPSHOT
TABLE 082. QIAGEN N.V.: BUSINESS PERFORMANCE
TABLE 083. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 084. QIAGEN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 084. QUEST DIAGNOSTICS INCORPORATED: SNAPSHOT
TABLE 085. QUEST DIAGNOSTICS INCORPORATED: BUSINESS PERFORMANCE
TABLE 086. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
TABLE 087. QUEST DIAGNOSTICS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 087. THERMO FISHER SCIENTIFIC INC: SNAPSHOT
TABLE 088. THERMO FISHER SCIENTIFIC INC: BUSINESS PERFORMANCE
TABLE 089. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 090. THERMO FISHER SCIENTIFIC INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 090. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 091. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 092. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 093. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY TECHNOLOGY
FIGURE 012. QPCR & MULTIPLEXING MARKET OVERVIEW (2016-2028)
FIGURE 013. NEXT-GENERATION SEQUENCING MARKET OVERVIEW (2016-2028)
FIGURE 014. LOAC & RT-PCR MARKET OVERVIEW (2016-2028)
FIGURE 015. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 016. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY FUNCTION
FIGURE 017. COMPANION DIAGNOSTICS MARKET OVERVIEW (2016-2028)
FIGURE 018. THERAPEUTIC & MONITORING MARKET OVERVIEW (2016-2028)
FIGURE 019. PROGNOSTIC MARKET OVERVIEW (2016-2028)
FIGURE 020. CANCER MARKET OVERVIEW (2016-2028)
FIGURE 021. SCREENING MARKET OVERVIEW (2016-2028)
FIGURE 022. RISK ANALYSIS MARKET OVERVIEW (2016-2028)
FIGURE 023. NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY APPLICATION
FIGURE 024. BIOMARKER DEVELOPMENT MARKET OVERVIEW (2016-2028)
FIGURE 025. CTC ANALYSIS MARKET OVERVIEW (2016-2028)
FIGURE 026. PROTEOMIC ANALYSIS MARKET OVERVIEW (2016-2028)
FIGURE 027. EPIGENETIC ANALYSIS MARKET OVERVIEW (2016-2028)
FIGURE 028. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA NEXT GENERATION GYNECOLOGICAL CANCER DIAGNOSTIC MARKET OVERVIEW BY COUNTRY (2016-2028)